Oral bacillus Calmette-Guérin vaccine against tuberculosis; why not?

dc.creatorMaia, Renata Monteiro
dc.creatorPinho, Rosa Teixeira de
dc.date2015-05-27T13:39:46Z
dc.date2015-05-27T13:39:46Z
dc.date2014
dc.date.accessioned2023-09-26T20:33:17Z
dc.date.available2023-09-26T20:33:17Z
dc.identifierMAIA, Renata Monteiro; PINHO, Rosa Teixeira de. Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?. Mem Inst Oswaldo Cruz, v.109, n.6, p.838-845, Sept. 2014.
dc.identifier1678-8060
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/10533
dc.identifier10.1590/0074-0276140091
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8859411
dc.descriptionThe bacillus Calmette-Guérin (BCG) vaccine is the only licensed vaccine for human use against tuberculosis (TB). Although controversy exists about its efficacy, the BCG vaccine is able to protect newborns and children against disseminated forms of TB, but fails to protect adults against active forms of TB. In the last few years, interest in the mucosal delivery route for the vaccine has been increasing owing to its increased capacity to induce protective immune responses both in the mucosal and the systemic immune compartments. Here, we show the importance of this route of vaccination in newly developed vaccines, especially for vaccines against TB.
dc.formatapplication/pdf
dc.languageeng
dc.publisherFundação Oswaldo Cruz
dc.rightsopen access
dc.subjectVaccine
dc.subjectBCG
dc.subjectTuberculosis
dc.subjectMucosal
dc.subjectIntradermal
dc.subjectOral
dc.subjectOral bacillus Calmette-Guérin
dc.subjectVacina BCG
dc.subjectTuberculose
dc.titleOral bacillus Calmette-Guérin vaccine against tuberculosis; why not?
dc.typeArticle


Este ítem pertenece a la siguiente institución